Literature DB >> 22057665

The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries.

Raymond Oppong1, Billingsley Kaambwa, Jacqueline Nuttall, Kerenza Hood, Richard D Smith, Joanna Coast.   

Abstract

When using the EQ-5D in European cross-national studies, there is no consensus over whether the European value set (EVS), country specific value sets (CVS) or UK value set (UKVS) should be used. Data on health outcomes were collected in 7 countries. EQ-5D index scores were generated for each country using all three value sets. QALYs gained over 4 weeks based on EQ-5D scores were also generated in order to investigate the implications for cost-utility analysis. EQ-5D scores obtained using the EVS were similar to values obtained using the CVS and UKVS in all countries. CVS-based EQ-5D scores were on average associated with a smaller baseline-to-week 4 change/improvement in all countries (except in Wales and Belgium) while UKVS-based EQ-5D scores showed the largest improvement over the same period for every country. With regards to cost-utility analysis, the results suggest that in most countries (with the exception of Belgium and Finland), using different tariffs to value EQ-5D would not have made a difference to the decisions based on the results of cost-utility analysis.

Entities:  

Mesh:

Year:  2011        PMID: 22057665     DOI: 10.1007/s10198-011-0360-9

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  30 in total

Review 1.  Methods for assessing responsiveness: a critical review and recommendations.

Authors:  J A Husted; R J Cook; V T Farewell; D D Gladman
Journal:  J Clin Epidemiol       Date:  2000-05       Impact factor: 6.437

2.  A single European currency for EQ-5D health states. Results from a six-country study.

Authors:  Wolfgang Greiner; Tom Weijnen; Martin Nieuwenhuizen; Siem Oppe; Xavier Badia; Jan Busschbach; Martin Buxton; Paul Dolan; Paul Kind; Paul Krabbe; Arto Ohinmaa; David Parkin; Montserat Roset; Harri Sintonen; Aki Tsuchiya; Frank de Charro
Journal:  Eur J Health Econ       Date:  2003-09

3.  Valuations of EQ-5D health states: are the United States and United Kingdom different?

Authors:  Jeffrey A Johnson; Nan Luo; James W Shaw; Paul Kind; Stephen Joel Coons
Journal:  Med Care       Date:  2005-03       Impact factor: 2.983

4.  Preference-Based EQ-5D index scores for chronic conditions in the United States.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

5.  US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?

Authors:  I-Chan Huang; Richard J Willke; Mark J Atkinson; William R Lenderking; Constantine Frangakis; Albert W Wu
Journal:  Qual Life Res       Date:  2007-04-06       Impact factor: 4.147

6.  A uniform time trade off method for states better and worse than dead: feasibility study of the 'lead time' approach.

Authors:  Nancy J Devlin; Aki Tsuchiya; Ken Buckingham; Carl Tilling
Journal:  Health Econ       Date:  2011-03       Impact factor: 3.046

Review 7.  Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Authors:  F Guillemin; C Bombardier; D Beaton
Journal:  J Clin Epidemiol       Date:  1993-12       Impact factor: 6.437

8.  Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.

Authors:  O Ström; F Borgström; S S Sen; S Boonen; P Haentjens; O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2007-02-28       Impact factor: 4.507

9.  Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions.

Authors:  Kimberley A Goldsmith; Matthew T Dyer; Peter M Schofield; Martin J Buxton; Linda D Sharples
Journal:  Health Qual Life Outcomes       Date:  2009-11-26       Impact factor: 3.186

10.  Generalized cost-effectiveness analysis for national-level priority-setting in the health sector.

Authors:  Raymond Hutubessy; Dan Chisholm; Tessa Tan-Torres Edejer
Journal:  Cost Eff Resour Alloc       Date:  2003-12-19
View more
  9 in total

1.  Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

Authors:  Klazien Matter-Walstra; Dirk Klingbiel; Thomas Szucs; Bernhard C Pestalozzi; Matthias Schwenkglenks
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

2.  A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.

Authors:  Devin Incerti; Jeffrey R Curtis; Jason Shafrin; Darius N Lakdawalla; Jeroen P Jansen
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

3.  Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults.

Authors:  Constantinos I Michaelidis; Richard K Zimmerman; Mary Patricia Nowalk; Michael J Fine; Kenneth J Smith
Journal:  J Gen Intern Med       Date:  2014-04       Impact factor: 5.128

4.  Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.

Authors:  Irina A Tikhonova; Huiqin Yang; Segun Bello; Andrew Salmon; Sophie Robinson; Mohsen Rezaei Hemami; Sophie Dodman; Andriy Kharechko; Richard C Haigh; Meghna Jani; Timothy J McDonald; Martin Hoyle
Journal:  Health Technol Assess       Date:  2021-02       Impact factor: 4.014

5.  Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China.

Authors:  SiNi Li; JianHe Li; LiuBao Peng; YaMin Li; XiaoMin Wan
Journal:  Rheumatol Ther       Date:  2021-04-24

Review 6.  Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies.

Authors:  Raymond Oppong; Sue Jowett; Tracy E Roberts
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

7.  Adjustment of foreign EQ-5D-3L utilities can increase their transferability.

Authors:  Lars Oddershede; Karin Dam Petersen
Journal:  Clinicoecon Outcomes Res       Date:  2015-12-15

8.  Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure.

Authors:  SiNi Li; JianHe Li; LiuBao Peng; YaMin Li; XiaoMin Wan
Journal:  Rheumatol Ther       Date:  2021-03-27

Review 9.  The impact of acute pneumococcal disease on health state utility values: a systematic review.

Authors:  Ryan O'Reilly; Sayako Yokoyama; Justin Boyle; Jeffrey C Kwong; Allison McGeer; Teresa To; Beate Sander
Journal:  Qual Life Res       Date:  2021-07-17       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.